GSK PLC (GSK)
43.50
+0.15
(+0.35%)
USD |
NYSE |
May 03, 16:00
43.50
0.00 (0.00%)
Pre-Market: 20:00
GSK Research and Development Expense (TTM): 8.034B for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.034B |
| December 31, 2023 | 7.747B |
| September 30, 2023 | 7.317B |
| June 30, 2023 | 6.907B |
| March 31, 2023 | 6.790B |
| December 31, 2022 | 6.738B |
| September 30, 2022 | 6.480B |
| June 30, 2022 | 6.848B |
| March 31, 2022 | 6.918B |
| December 31, 2021 | 6.980B |
| September 30, 2021 | 6.662B |
| June 30, 2021 | 6.183B |
| March 31, 2021 | 6.165B |
| December 31, 2020 | 6.145B |
| September 30, 2020 | 6.209B |
| June 30, 2020 | 6.222B |
| March 31, 2020 | 6.039B |
| December 31, 2019 | 5.828B |
| September 30, 2019 | 5.611B |
| June 30, 2019 | 5.412B |
| March 31, 2019 | 5.242B |
| December 31, 2018 | 5.189B |
| September 30, 2018 | 5.410B |
| June 30, 2018 | 5.494B |
| March 31, 2018 | 5.844B |
| Date | Value |
|---|---|
| December 31, 2017 | 5.776B |
| September 30, 2017 | 5.416B |
| June 30, 2017 | 5.257B |
| March 31, 2017 | 4.922B |
| December 31, 2016 | 4.899B |
| September 30, 2016 | 5.252B |
| June 30, 2016 | 5.322B |
| March 31, 2016 | 5.291B |
| December 31, 2015 | 5.438B |
| September 30, 2015 | 5.388B |
| June 30, 2015 | 5.447B |
| March 31, 2015 | 5.565B |
| December 31, 2014 | 5.672B |
| September 30, 2014 | 5.855B |
| June 30, 2014 | 5.910B |
| March 31, 2014 | 6.160B |
| December 31, 2013 | 6.143B |
| September 30, 2013 | 6.248B |
| June 30, 2013 | 6.332B |
| March 31, 2013 | 6.183B |
| December 31, 2012 | 6.309B |
| September 30, 2012 | 6.193B |
| June 30, 2012 | 6.298B |
| March 31, 2012 | 6.491B |
| December 31, 2011 | 6.427B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.412B
Minimum
Jun 2019
8.034B
Maximum
Mar 2024
6.562B
Average
6.571B
Median
Research and Development Expense (TTM) Benchmarks
| AstraZeneca PLC | 11.11B |
| Novo Nordisk A/S | 4.992B |
| Pfizer Inc | 10.67B |
| Sanofi SA | 7.471B |
| Moderna Inc | 4.777B |